Safety of Romiplostim (Nplate) in Patients Who Have Failed to Achieve Platelet Engraftment Following Umbilical Cord Blood Transplant
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Romiplostim (Primary)
- Indications Cord blood stem cell transplant rejection; Stem cell engraftment
- Focus Adverse reactions
- 12 Apr 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 12 Apr 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2020.
- 18 Feb 2019 Status changed from recruiting to active, no longer recruiting.